Potential Capitulation Bounce Setting Up in ETRM

info@mybeststockpicks.com 1-(844)-30-STOCK
To Get Update On Mobile Text STOCKS to 67076
The #1 Newsletter for Highly Profitable Penny Stock Alerts
our new pick 

New Opportunity:  EnteroMedics Inc.  (NasdaqCM: ETRM)

We would like to bring to your attention a brand new NASDAQ trade opportunity that appears to suggest significant upside opportunity in the short-term.

The last few alerts unfortunately have not been superb for us, but if you recall, at one point we were sitting with alerts that provided us with over 400% in upside. As is the case with trading, unfortunately with the gains come the losses.

Today’s alert opened at 1.96 and rallied to a high of 2.05 for upside of 4%, however we are not overly excited about that. Our goal is to focus on trade opportunities that provide you with massive upside volatility.

As such, we have come across a brand new alert that we believe may be positioned for superb upside.

Symbol:  ETRM

Company:  EnteroMedics Inc.

Quote:  http://finance.yahoo.com/q?s=ETRM

Latest News:  http://finance.yahoo.com/q/h?s=ETRM+Headlines

Company Website:  http://www.enteromedics.com

New Trade Alert: EnteroMedics Inc. (NASDAQ: ETRM)

This NASDAQ listed company trades at only 14 cents, and has recently traded as high as 1.00. Make note, our goal is not to anticipate such a move. This only goes to demonstrate the type of volatility this company has experienced in the recent past.

ETRM has a 20 day moving average at 0.17, which acts as a near term resistance above current valuation by 21%.

If the 20 day moving average  is surpassed the next possible resistance level could be the 50 day moving average at 0.22 for upside of 57% from current valuation.

What You Need To Know:

  • ETRM has a small trading float of just 26.60M, which suggests the stock could launch higher on any additional influx of interest.
  • ETRM is making real money, with trailing revs already coming in at $561.00k.
  • ETRM is starting to see major topline growth, with quarterly y/y revs increasing at 249%.
  • ETRM is showing a clear surge in interest, with volume over the last couple weeks tracking 160% above its recent average levels.
  • ETRM is coming off an RSI trough under 40, pointing to a massively oversold stock now heading back the other way.
  • etrm-chart

ETRM experienced what may potentially prove to be a reversal, after it jumped during today’s trading after yesterday’s reversal candle.

ETRM has witnessed incredible volume over the past few weeks, suggestive of increased opportunity to experience momentum.

Please note that ETRM could be extremely volatile and that we are monitoring this for short term gain potential only.

ETRM reported breaking news today that appears to have been received well by markets: EnteroMedics Announces Appointment of Scott Youngstrom as Chief Financial Officer and Chief Compliance Officer

ST. PAUL, Minn., Sept. 7, 2016 /PRNewswire/ — EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the appointment of Scott Youngstrom as Chief Financial Officer and Chief Compliance Officer, effective October 3, 2016.  Scott will succeed Greg Lea, EnteroMedics’ current Chief Financial Officer and Chief Compliance Officer, who will be retiring from the Company effective October 3, 2016, as previously announced.

ETRM stock

About ETRM

ETRM (EnteroMedics Inc.) EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses.

ETRM develops the Maestro Rechargeable System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It has collaboration with Mayo Clinic for the development and testing of products for the treatment of obesity.

,

Greg Folin

 

DISCLAIMER

The disclaimer is to be read and fully understood before using our site Mybeststockpicks.com also refered to as MBSP. This report/release/video profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. Never invest in any stock discussed on Mybeststockpicks.com or MBSP’s newsletter unless you can afford to lose your entire investment. Never listen to anyone on MBSP message boards or private messages sent by any user or member who offers any sort of financial advice. Please consult with a certified financial advisor before making any investment decisions. MBSP and any affiliates and information providers make no implied or expressed warranties on the information provided. Please verify quotes with your investment manager before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. Any stock or featured companies on MBSP web site and/or newsletter involves a high degree of risk and volatility, and all investors should know that they may lose a portion or all of their investment if they decide to purchase any stock mentioned or talked about on MBSP or message boards. MBSP makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or members and does not guarantee the correctness, completeness or quality of information and statements presented on MBSP. Any such information or statements should be deemed apocryphal and opinions only. Neither MBSP, nor any of its affiliates, are registered investment advisors or broker dealers and do not make recommendations to buying, holding, or selling of any securities. MBSP simply provides a starting point for site members and viewers to compare their own thoughts against those here on the message boards at MBSP. The onus is on site members and viewers to complete their own due diligence. MBSP members and viewers should always make their own financial decisions. The accuracy and completeness of the information within any report, newsletter or on website message boards is only as reliable as the information that is provided by MBSP members and users. MBSP does not verify the information, and makes no warranty that the information is accurate. MBSP members, readers and viewers are cautioned that small and micro-cap stocks are high-risk investments and that all investment dollars can be lost. We suggest you consult a professional investment advisor before purchasing any stock. All opinions and postings expressed on MBSP web site are the opinions of MBSP members and users . All information concerning any company is provided by the members and users that create the information box on each board. MBSP recommends you use the information found here on the site and boards as an initial starting point for conducting you own research and conduct your own due diligence (also known as “DD” on any company you read about here at MBSP, in order to determine your own personal opinion of the company before investing in these or any other companies. MBSP assumes all information to be truthful and reliable. However, we cannot and do not warrant or guarantee the accuracy of this information. MBSP is NOT an Investment Advisor, Financial Planning Service or a Stock Brokerage Firm and in accordance with such MBSP is not offering investment advice or promoting any investment strategies. MBSP is not offering securities for sale or solicitation of any offer to buy or sell securities. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. On occasion, MBSP may receive compensation from a third party in relation to the companies being profiled in its Newsletters sent to our members. In such a case MBSP directly mentions such compensations at the bottom of this disclaimer along with the exact form and amount of compensation.  in relation to the companies being profiled in its Newsletters sent to our members. In such a case MBSP directly mentions such compensations at the bottom of this disclaimer along with the exact form and amount of compensation. Do your own research and due diligence before investing in any company. MBSP merely is providing information and is in no way or manner suggesting an investment in any company or investment opportunity. You are the investor and are making decisions for yourself. report/release/video profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.

 

2012 www.mybeststockpicks.com. All rights reserved.To Unsubscribe Click Here
Total Views: 5584 ,